ECSP992970A - SEQUENCE OF THE GENE RELATED TO ANGIOPOYETINO SCARFACE 3 - Google Patents

SEQUENCE OF THE GENE RELATED TO ANGIOPOYETINO SCARFACE 3

Info

Publication number
ECSP992970A
ECSP992970A ECSP992970A ECSP992970A EC SP992970 A ECSP992970 A EC SP992970A EC SP992970 A ECSP992970 A EC SP992970A EC SP992970 A ECSP992970 A EC SP992970A
Authority
EC
Ecuador
Prior art keywords
scarface
proteins
angiopoyetino
sequence
gene related
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Paul Robert Rosteck
Stanley Gene Burgett
Josef Georg Heuer
Rebecca Ann Leonard
Patanjali Raghavac Sankhavaram
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP992970 priority Critical patent/ECSP992970A/en
Publication of ECSP992970A publication Critical patent/ECSP992970A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención proporciona compuestos de ácido nucleico, de scarface 3, sus proteínas y fragmentos aislados, estando dichas proteínas Scarface 3 relacionadas con la familia de la angiopoyetina. También se proporcionan vectores y células huésped heterólogas transformadas para expresar Scarface 3, procedimientos para la identificación de compuestos que se unen a, y/o modulan la actividad de, dichas proteínas Scarface 3, además de procedimientos para tratar cáncer y la mielosupresión, y composiciones farmacéuticas que comprenden Scarface 3 o sus análogos.The invention provides scarface 3 nucleic acid compounds, their proteins and isolated fragments, said Scarface 3 proteins being related to the angiopoietin family. Also provided are vectors and heterologous host cells transformed to express Scarface 3, procedures for the identification of compounds that bind to, and / or modulate the activity of, said Scarface 3 proteins, in addition to methods for treating cancer and myelosuppression, and compositions. Pharmaceuticals comprising Scarface 3 or its analogues.

ECSP992970 1999-06-01 1999-06-01 SEQUENCE OF THE GENE RELATED TO ANGIOPOYETINO SCARFACE 3 ECSP992970A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP992970 ECSP992970A (en) 1999-06-01 1999-06-01 SEQUENCE OF THE GENE RELATED TO ANGIOPOYETINO SCARFACE 3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP992970 ECSP992970A (en) 1999-06-01 1999-06-01 SEQUENCE OF THE GENE RELATED TO ANGIOPOYETINO SCARFACE 3

Publications (1)

Publication Number Publication Date
ECSP992970A true ECSP992970A (en) 2000-01-27

Family

ID=42043959

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP992970 ECSP992970A (en) 1999-06-01 1999-06-01 SEQUENCE OF THE GENE RELATED TO ANGIOPOYETINO SCARFACE 3

Country Status (1)

Country Link
EC (1) ECSP992970A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US12503503B2 (en) 2018-10-29 2025-12-23 Hoffmann-La Roche Inc. Bispecific anti-VEGF/ANG2 antibody formulation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US12503503B2 (en) 2018-10-29 2025-12-23 Hoffmann-La Roche Inc. Bispecific anti-VEGF/ANG2 antibody formulation

Similar Documents

Publication Publication Date Title
JOP20220079A1 (en) A multispecific binding protein for cancer treatment
BR112021022874A2 (en) epcam binding proteins and methods of use
BR9711795A (en) Peptides having antiproliferative properties
MX2020009514A (en) ANTI-CLAUDIN 18.2 ANTIBODIES (CLDN18.2).
AR053063A2 (en) SUBSTANTIALLY PURIFIED PROTEIN AND PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT
ES2096750T3 (en) USEFUL RETROVIRIC VECTORS FOR GENIC THERAPY.
FR17C1046I1 (en) NEW B7-4 MOLECULES AND THEIR USES
BR0316435A (en) Genetic products differentially expressed in and use of tumors
DK1103564T3 (en) Cancer antigens based on the tumor suppressor gene WT1 product
BR112022012327A2 (en) ANTIBODIES OR FRAGMENTS THEREOF, NUCLEIC ACID, VECTOR AND HOST CELL
WO2004053079A3 (en) Compositions, splice variants and methods relating to ovarian specific genes and proteins
TR199902053T2 (en) Compounds for immunotherapy of prostate cancer and methods for their use.
DE60035517D1 (en) GL50 MOLECULES, AND USES THEREOF
BR0015137A (en) Neisserial antigenic peptides
ATE300619T1 (en) HUMAN CHECKPOINT KINASE, HCDS1, COMPOSITIONS AND METHODS
ATE473283T1 (en) DNA EXPRESSION VECTORS
EP0962530A3 (en) Gene sequence encoding for the angiopoietin related protein scarface 1
BR9712575A (en) Process for restoring cells that have a mutated p53 protein, a p53-dependent transactivation activity, uses a single chain antibody capable of specifically binding a mutated p53 protein, and a coding nucleic acid, molecule 11d3 or a variant, nucleic acid and composition
SV1999000069A (en) ANGIOPOYETIN RELATED TO SEQUENCE OF GEN 3 IN FACE SCAR REF. X-12261
SE0301987D0 (en) New polypeptide
DE59712554D1 (en) RECOMBINANT EXPRESSION OF S-LAYER PROTEINS
ZA202310639B (en) Interleukin 15 variants
BR9915513A (en) Potassium channel interactants and uses for such
DE69733491D1 (en) Gene product overexpressed in cancer cells
DE60137222D1 (en) HUMAN TRP-SIMILAR CALCIUM CHANNEL PROTEIN-2 TLCC-2